0001144204-14-014331.txt : 20150128 0001144204-14-014331.hdr.sgml : 20150128 20140310101154 ACCESSION NUMBER: 0001144204-14-014331 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20140310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AmpliPhi Biosciences Corp CENTRAL INDEX KEY: 0000921114 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911549568 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 BUSINESS PHONE: 650-888-2422 MAIL ADDRESS: STREET 1: 4870 SADLER ROAD STREET 2: SUITE 300 CITY: GLEN ALLEN STATE: VA ZIP: 23060 FORMER COMPANY: FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/ DATE OF NAME CHANGE: 19940331 CORRESP 1 filename1.htm

  

2000 Pennsylvania Ave., NW
Washington, D.C.
20006-1888

 

Telephone: 202.887.1500
Facsimile: 202.887.0763

 

www.mofo.com

 

 

morrison & foerster llp

 

new york, san francisco,
los angeles, palo alto,
sacramento, san diego,
denver, northern virginia,
washington, d.c.

 

tokyo, london, berlin, brussels,
beijing, shanghai, hong kong,
singapore

 

 

 

March 10, 2014

 

BY EDGAR

 

Amy Reischauer

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

  Re: AmpliPhi Biosciences Corporation
    Amendment No. 1 to Registration Statement on Form 10-12G
    Filed February 4, 2014
    File No. 000-23930

  

Dear Ms Reischauer:

 

On behalf of AmpliPhi Biosciences Corporation (the “Company”), the Company hereby requests until March 31, 2014 to respond to the comments to the Company’s Amendment No. 1 to Registration Statement on Form 10-12G contained in the Staff’s letter dated February 24, 2014.

 

Thank you for your assistance regarding this matter. If you have any questions please contact me at (202) 887-1571 or by email at sthau@mofo.com.

 

Sincerely,

 

/s/ Stephen Thau

 

Stephen Thau

 

 

cc: Philip J. Young, AmpliPhi Biosciences Corporation

 

 

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#`.\#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BO+YO%6 MN>%O'L^GWKW6J:-=L+6Q9E3S%N_+5PA*J.&W]3TZ]C6I\--3UK5TUV?6M2:Y MFM=2ELUC1%6)`F/NX&3R2.2>,4`=Y17GVBZEK/C*]\2S1ZM-ID.FWCV5G#`B M'#(.9)=RG=DD?+P,?G5_P?XBO/&'P[34IV:TO622.26W`^^A(WIN!&#C/.>] M`'945X=I'C7Q+?>'/#[VFJ7T_B34;E@D-Q;QI:31(Y#X;:.B@9PV<]J]!^)V MHZAHW@/4-6TN^EM+NT"NC(JL&RP4A@P/&#VQ0!V%%>::%XAU>^\=6&FZ??7M MU:16GFZO%J,*1M"67,9CPJL\(-2M6U+4#Y$$9&FZG:B&XMSD[F)4`.IR.>H_6@#OZ*\_P!&U+6/ M&.K^)?+U6;3+?3+MK&TB@1"=ZCF23<#NR<87@8_.M#P1KU[XU\!QWEQ(UG?, M9())[8#[Z-C>@8$8..A![T`=A17C,?CC7K+1I=+\1:A)97LT$EQI&L0QILNB MH;$<@*E0V<<<9X^I]-O\`]^(?^P?-_Z`:W+/_CQM_P#KFO\` M*@">BN>\<3WEEX.U._L+V:TN;.W>>-XPIR54D`A@017/>"M0UO69]+N)K[4Q M&ME%<7BW<$0AN?,1@/**KD;6`/7H>E`'H5%<)9:KJ?BGQOXATN/4)M-L-&\J M%5MU3S)I7!;>Q8'Y1C``Z]ZM^`O$%_XET+4(M1D7[;87LUA)=0*%$I3I(HY` M.#TZ9'X4`=A17C^GZYXBO;K7M/.K:T\MMJYTZUO(+>!HH%.`KS?)S@GG`'X5 MZ/J9NU\(3R)?LEW'9F074`4Y=5SN`((P2/3H:`-FBO%M$\9^(=1L?"B66I7E MSKNHN);JWNK>-+9[<$^8RMM'0`?=)/7BN_\`'E]K]CI-L_A^W>XE-POVF.`I MYY@&=_E!N"W3L<9Z4`=517G_`('\3MK/B._LVU+4?W-LC?V9JEHL5Q"V[YFW M*`'4Y`]15;79_$.E>+O#6F-XBNFCU>[NA.(XHE$<:C=&J90D8!`).*X/P=KOB#7]+\/W$VJ:I#< M7`^T7-Q-!"+.5%E"F,$+N#,&X.1R.]`'K-0W7_'L_P"'\ZY'XI:GJ6A^";C5 M=*OY;2ZMI(\%41E<,X4A@P/8]L5DZ9KVK7OCC^S+"\O;K3+:UW:HFHP)%)!* MW,>SY58Y^A&.]`'6V/A:UL;NYNOME]&QN+QQ=RF>99YMX:0]7Z<$]ZWJ*`.=N_!FFW%[?74$UY8OJ"A;U;. M;RUN,#&6&#AL<;EP?>M&+1+*TT)=&L%:RLTB\J,6QVE%]CSS[^]:-%`'&I\, MO#Z:!;Z,K7WV>UG%Q:/]H/F6TF#4-/B\E+D3D/+'G.R3'#CZU)KGA" MQ\0:G8ZA=W-\D]BV^V\F;8L;]V`QR>W-=!10!CZSX;LMQ9GMY M;>8QLK,,$Y'7CL>/4&G:;X=L]-U&XU+?/ MM:U%`'/7?@W3KB_OKR">\L9;]`EY]CF\L3X&`6&#AL<;EP?>M&VT6ST_1(]( MTU6L;6)/+B%N<,@]B<\^Y]:T**`.9?P)H\_AI]`O#,Q6T4;8RB!3CV%`%'7=$@\0:5+ MIMU/$!8AIZPD6I2-+>;;O!F9AAB3C M/(ZXQ6_/HMO-X?&BK+/#;"!;<-$^'"``8SCT&*TJ*`./'PVT)='T[35DOU33 M)O.L9UN");8]PK`?=/H.W3U MS6Q10!D:=X=L]/U2?5&EN+K49HA"USXG@24;6>!]KX[C. M#UKF[;X=:5:V6G6"7NJ&QT^9)K>U-S^[#*VX9`'S#/.#FNOHH`Q?$WABR\6: M7_9NHRW2VA8,\<$NS?@Y&3CL0#5"Y\%Z:-1M]96>]74K>W^S-<+/AIX^PDP, 3-CJ..PKJ:CF0R0L@QD^M`'__V3\_ ` end